Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Irvin Ho"'
Autor:
Bolesław L, Osinski, Aïcha, BenTaieb, Irvin, Ho, Ryan D, Jones, Rohan P, Joshi, Andrew, Westley, Michael, Carlson, Caleb, Willis, Luke, Schleicher, Brett M, Mahon, Martin C, Stumpe
Publikováno v:
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 35(12)
To achieve minimum DNA input requirements for next-generation sequencing (NGS), pathologists visually estimate macrodissection and slide count decisions. Unfortunately, misestimation may cause tissue waste and increased laboratory costs. We developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3bf91888059c2e7b82d7513f57d0fae9
https://pubmed.ncbi.nlm.nih.gov/36198869
https://pubmed.ncbi.nlm.nih.gov/36198869
Publikováno v:
PSB
Patient responses to cancer immunotherapy are shaped by their unique genomic landscape and tumor microenvironment. Clinical advances in immunotherapy are changing the treatment landscape by enhancing a patient's immune response to eliminate cancer ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d195ebd917f370744effa22190a6b7c
https://pubmed.ncbi.nlm.nih.gov/30864330
https://pubmed.ncbi.nlm.nih.gov/30864330
Publikováno v:
Cancer Immunology Research. 8:B57-B57
Patient responses to cancer immunotherapy are shaped by their unique genomic landscape and tumor microenvironment. Clinical advances in immunotherapy are changing the treatment landscape by enhancing a patient’s immune response to eliminate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db500e29a0fdd9aaa97ec606f77d4d4f
https://doi.org/10.1158/2326-6074.tumimm18-b57
https://doi.org/10.1158/2326-6074.tumimm18-b57
Autor:
Boleslaw Osinski, Caleb Willis, Tim Taxter, Irvin Ho, Stephen S.F. Yip, Hannah Weiss, Timothy L. Tan, Lingdao Sha, Nike Beaubier, Brett Mahon
Publikováno v:
Journal of Pathology Informatics
Journal of Pathology Informatics, Vol 10, Iss 1, Pp 24-24 (2019)
Journal of Pathology Informatics, Vol 10, Iss 1, Pp 24-24 (2019)
Background: Tumor programmed death-ligand 1 (PD-L1) status is useful in determining which patients may benefit from programmed death-1 (PD-1)/PD-L1 inhibitors. However, little is known about the association between PD-L1 status and tumor histopatholo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2307ddd4823beab86f168188460b3c7
https://doi.org/10.4103/jpi.jpi_24_19
https://doi.org/10.4103/jpi.jpi_24_19